The first patient has been dosed in the DESTINY-Lung06 phase 3 trial evaluating Enhertu plus pembrolizumab versus pembrolizumab, platinum-based chemotherapy and pemetrexed as a first-line treatment in patients with unresectable, locally advanced or metastatic HER2 overexpressing and PD-L1 TPS less than 50% non-squamous non-small cell lung cancer. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (AZN).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca reports gefurulimab met primary endpoint in PREVAIL Phase 3 trial
- AstraZeneca’s New Study on Chronic Kidney Disease: Potential Market Impact
- FDA moves to accelerate biosimilar development, lower drug costs
- AstraZeneca’s New Phase I Study on AZD0292: Key Insights for Investors
- AstraZeneca Advances PNH Treatment with Danicopan Study Update